TrialCirculation2026

IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.

Moritz J Hundertmark et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.